{"title":"Current research status of diagnosis and therapy in mixed phenotype acute leukemia","authors":"Jia-yuan Chen, Yingjun Chang, H. Wei","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.04.002","DOIUrl":null,"url":null,"abstract":"Mixed phenotype acute leukemia (MPAL) is an uncommon subtype of acute leukemia (AL). It is characterized by the expression of multi-lineage immunophenotypic markers representing myeloid, T or B lymphoid lineage in leukemia cells. The diagnosis of MPAL refers to the World Health Organization (WHO) classification of myeloid neoplasms and AL proposed in 2016. Given the low prevalence and inferior prognosis of MPAL, it′s difficult to choose the optimal treatment for MPAL patients. Pathogenesis of MPAL remains largely unknown. Due to the development of biologic technology, researchers now have a better comprehension of this rare disease. This article reviews the advances of diagnosis, pathogenesis and treatment in MPAL. \n \n \nKey words: \nLeukemia, biphenotypic, acute; Diagnosis; Therapy; Pathogenesis mechanisms","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"283-288"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.04.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mixed phenotype acute leukemia (MPAL) is an uncommon subtype of acute leukemia (AL). It is characterized by the expression of multi-lineage immunophenotypic markers representing myeloid, T or B lymphoid lineage in leukemia cells. The diagnosis of MPAL refers to the World Health Organization (WHO) classification of myeloid neoplasms and AL proposed in 2016. Given the low prevalence and inferior prognosis of MPAL, it′s difficult to choose the optimal treatment for MPAL patients. Pathogenesis of MPAL remains largely unknown. Due to the development of biologic technology, researchers now have a better comprehension of this rare disease. This article reviews the advances of diagnosis, pathogenesis and treatment in MPAL.
Key words:
Leukemia, biphenotypic, acute; Diagnosis; Therapy; Pathogenesis mechanisms
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
